CD274 and neoplasm: The anti-tumor effect of anti-PD-1/PD-L1 immunotherapy is not mediated by the antibody itself, but by tumor antigen-specific T cells suppressed by PD-1/PD-L1 immune checkpoint mechanism [43,44].